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 Non-white groups had better or equivalent capture of risk factors prior to diagnosis 
compared to white groups
 Risk factor levels at diagnosis were more favourable for south Asian and Black groups
 Initiation of diabetes therapy was faster for non-white groups relative to white groups
 Downstream inequalities in type 2 diabetes do not appear to stem from inequalities in initial 
diagnosis
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2Abstract 
Aims: To characterize ethnic differences in the severity and clinical management of type 2 diabetes 
at initial diagnosis. 
Methods: An observational cohort study of 179,886 people with incident type 2 diabetes between 
2004 and 2017 in the Clinical Practice Research Datalink was undertaken; 63.4% of the cohort were of 
white ethnicity, 3.9% south Asian, and 1.6% black. Ethnic differences in clinical profile at diagnosis, 
consultation rates, and risk factor recording were derived from linear and logistic regression. Cox-
proportional hazards regression was used to determine ethnic differences in time to initiation of 
therapeutic and non-therapeutic management following diagnosis. All analyses adjusted for age, sex, 
deprivation, and clustering by practice.
Results: In the 12 months prior to diagnosis, non-white groups had fewer consultations compared to 
white groups, but risk factor recording was better than or equivalent to white groups for 9/10 risk 
factors for south Asian groups and 8/10 risk factors for black groups (p<0.002). Blood pressure, BMI, 
cholesterol, eGFR, and CVD risk levels were more favourable in non-white groups, and prevalence of 
macrovascular disease was significantly lower (p<0.003). Time to initiation of antidiabetic treatment 
and first risk assessment was faster in non-white groups relative to white groups, while time to risk 
factor measurement and diabetes review was slower.
Conclusions: We find limited evidence of systematic ethnic inequalities around the time of type 2 
diabetes diagnosis. Ethnic disparities in downstream consequences may relate to genetic risk factors, 
or manifest later in the care pathway, potentially in relation to long-term risk factor control. 
31.0 Introduction
Marked ethnic differences in the risk of long-term vascular outcomes among people with type 2 
diabetes have been established in UK populations.(1,2) The extent to which these inequalities stem 
from modifiable factors such as healthcare usage or quality of diabetes management remains unclear. 
Given that inequalities can accumulate over time, it is vital to identify where along the care pathway 
differences by ethnicity may arise. Though equity of service provision is a central tenet of the National 
Health Service (NHS) (3), recent studies have highlighted ethnic differences in access to healthcare, 
treatment provision and risk factor control. (4–8) 
In the UK, the collection of ethnicity data via official statistics has been mandated since the Race 
Relations Act of 1968 as a vital first step towards identifying and actively tackling ethnic inequalities. 
The 16 ethnic group categories defined by the 2001 Census for England and Wales currently form the 
national standard for mandatory ethnicity data collection across the National Health Service. Ethnicity 
is self-reported by individuals at either initial registration with their general practitioner or during 
consultation, and intended to reflect the individuals own self-perception of belonging to, or 
identifying with a certain social group.(9,10) 
Prior to initial diagnosis, there may be differences by ethnicity in consultation rates and measurement 
of risk factors, which may impact upon the timeliness of diagnosis and severity of disease at initial 
presentation. Delays in diagnosis may result in delays in initiation of therapeutic and non-therapeutic 
management, which may further compound existing inequalities. Though guidelines exist for 
managing type 2 diabetes in the UK, the extent to which these are followed may differ by ethnic 
group, leading to inequalities in the downstream consequences of type 2 diabetes.(8,11). The 2018 
UK national diabetes audit identified inequalities by age, region, diagnosed serious mental illness and 
learning disabilities, but did not explore differences by ethnicity, leaving a critical gap in the evidence 
base.(12) 
The aims of this study were to (1) Quantify ethnic differences in risk factor levels and co-morbidities 
at the time of initial diagnosis, (2) Compare consultation rates and completeness of process of care 
4measures between ethnic groups in the 12 months preceding type 2 diabetes diagnosis, (3) 
Determine whether the time to initiation of therapeutic and non-therapeutic management following 
initial diagnosis differed by ethnic group.
2.0 Methods
2.1 Study design and population
An observational cohort study utilizing the Clinical Practice Research Datalink (CPRD) was undertaken. 
The CPRD is a clinical research database containing anonymised longitudinal primary care records for 
approximately 15 million people from 714 general practices. The CPRD population has been shown to 
be representative of the UK population with respect to age, gender, and ethnicity.(13) 
Type 2 diabetes was identified using an adjudication algorithm developed to minimize 
misclassification of diabetes status and type in electronic health records.(14) Briefly, the algorithm 
assigns an initial diabetes type based on clinical Read codes (15) - C10E for type 1 diabetes and C10F 
for type 2 diabetes-  and then applies a series of logic rules to assign a final diabetes status by 
identifying congruent or contradictory evidence on age at diagnosis, diabetes medications (excluding 
individuals on metformin only as these may be indicated for conditions other than type 2 diabetes 
such as polycystic ovarian syndrome or pre-diabetes), hyperglycaemia (HbA1c≥6.5% or 48 mmol/mol, 
or fasting/ random/ unspecified glucose≥11.1 mmol/l) and presence of diabetes process of care 
codes. For individuals with a prescription for antidiabetic medication in the 12 months preceding the 
first ever type 2 diabetes diagnosis, the diagnosis date was moved forward to the date of prescription 
as it was deemed plausible that the prescription was related to the initial diagnosis. As 
misclassification of prevalent diagnoses as incident diagnoses is more likely around the time of initial 
registration with the general practitioner, a minimum registration period of six months prior to initial 
diagnosis of type 2 diabetes was required.(16) Adults aged 18 and over registered between 2004 and 
52017, with at least six months of continuous registration prior to diagnosis of type 2 diabetes (the 
earliest of diagnosis date or medication date where applicable) were included in the study.
2.2 Covariates
Self-reported ethnicity, identified using Read codes, was collapsed into the five categories of the 2001 
UK census (white, south Asian, black African/Caribbean, mixed, and other). For individuals with more 
than one ethnicity code on their primary care record, a previously developed algorithm was used to 
assign a best ‘single’ ethnicity – based on the most commonly, and most recently recorded codes 
(Supplementary material, Figure S1).(17) Age at diagnosis was calculated by subtracting year of birth 
from year of diagnosis. Deprivation was measured using quintiles of the 2015 Index of Multiple 
Deprivation (IMD) – a measure of small area deprivation based on an individual’s home postcode.(18) 
For people with linkage to Office for National Statistics data, quintiles of IMD were derived from the 
individual’s home postcode. For the 40% of people without linkage, quintiles were derived from the 
postcode of the individual’s general practice. 
Baseline risk factors were identified from the most recently recorded value in the 12 months 
preceding type 2 diabetes diagnosis (see supplementary table S3 for all code lists). These included 
glycated haemoglobin (HbA1c), fasting blood glucose (FBG), systolic and diastolic blood pressure (SBP, 
DBP), body mass index (BMI), total cholesterol, serum creatinine, consultations (face-to-face or 
telephone), smoking status ( ‘Ever smoker’, and ‘Never smoker’), alcohol consumption ( ‘Non-drinker’, 
‘Moderate drinker’, and ‘Heavy drinker’), and family history of cardiovascular disease (CVD). Risk 
assessments included ten-year CVD risk and the NHS health check. The CVD risk score, was 
categorized into “≤ 10% risk of developing CVD in the next ten years” and “>10% risk of developing 
CVD in the next ten years”.
Pre-diabetic states included coded pre-diabetes, family history of diabetes, and gestational diabetes 
(for women only). Co-morbidities were considered present at baseline if recorded at any time prior to 
6diagnosis.  Macrovascular co-morbidities included hypertension, coronary heart disease (CHD, 
including myocardial infarction and angina), stroke, and heart failure. Microvascular co-morbidities 
included chronic kidney disease (CKD), retinopathy, and neuropathy. 
To examine diabetes management following initial diagnosis, the date of the first antidiabetic 
medication prescription (including oral antidiabetic agents and insulin), consultation, risk factor 
measurement, diabetes review (including retinopathy screening, foot examination, and offer of 
dietary advice), offer of structured diabetes education, and risk assessment following diagnosis was 
extracted.
2.3 Statistical analysis
As individuals attending the same general practice may have similar levels of care provision and 
clinical coding, multilevel modelling was used to account for the clustering of people within practices. 
Ethnic differences in clinical characteristics at diagnosis were derived from multilevel multivariable 
linear regression, (for age at diagnosis, HbA1c, FBG, SBP, DBP, BMI, total cholesterol, serum 
creatinine, and eGFR) and multilevel multivariable logistic regression (for deprivation quintile, 
presence of pre-diabetes, family history of diabetes, gestational diabetes, family history of 
cardiovascular disease, any macrovascular disease, any microvascular disease, smoking status, alcohol 
consumption, CVD risk, and use of antihypertensive or lipid lowering drugs) and adjusted for age at 
diagnosis, sex, and deprivation. Multilevel multivariable logistic regression adjusted for age at 
diagnosis, sex, and deprivation was used to determine ethnic differences in the odds of having each 
risk factor recorded in the 12 months prior to diagnosis. Multivariable Cox-proportional hazards 
regression adjusting for age at diagnosis, sex, deprivation, raised HbA1c at baseline (>7.5%/53 
mmol/L), and clustering by practice was used to compare time to initiation of therapeutic and non-
therapeutic diabetes management between ethnic groups. Follow-up time began at the date of type 
2 diabetes onset and ended at the earliest of: first antidiabetic prescription or care process, leaving 
the CPRD, last data collection, or death.
72.4 Sensitivity Analysis
We conducted a sensitivity analysis comparing outcomes for those of unknown ethnicity to those of 
any known ethnicity. As the recording of ethnicity was financially incentivised under the Quality and 
Outcomes Framework from 2006-2011, and forms a core component of the annual NHS Health 
Check(19) and the NHS diabetes management guidelines(20),  the recording of ethnicity can be 
considered a marker of engagement with primary care. We hypothesized that individuals with missing 
ethnicity would have poorer risk factor control at diagnosis, lower consultation rates, worse capture 
of risk factors prior to diagnosis and slower initiation of therapeutic and non-therapeutic 
management relative to those with ethnicity recorded. 
3.0 Results
From 241,891 individuals diagnosed with type 2 diabetes between April 1st, 2004 and December 31st, 
2016 in the CPRD, 179,886 adults aged 18 or over, with at least 6 months registration prior to initial 
diagnosis, were included in the study (Figure 1). Within this population, 5% (n=8,871) had been 
prescribed an antidiabetic medication in the year prior to diagnosis and had their diagnosis date 
moved backwards. Ethnicity was recorded for 70% of the cohort (n=126,331), of whom 90.2% were 
white (n=113,988), 5.5% were south Asian (n=6,970), 2.3% were black African/Caribbean (n=2,944), 
and 1.9% were of other ethnicities, including mixed (n=2,409). Comparisons between the white, south 
Asian and black ethnic groups are reported below.  
3.1 Clinical characteristics at initial diagnosis
Crude ethnic differences in clinical characteristics at initial diagnosis are described in table 1 and 
adjusted differences are illustrated in figure 2. After adjustment for sex, deprivation, calendar year 
and clustering by practice, age at diagnosis was estimated to be 9.8 years earlier in south Asian 
8groups than white groups (95%CI -10.14, -9.45) and 7 years earlier in black groups (95%CI -7.46, -
6.44) relative to white.  Black groups were overrepresented in the least affluent deprivation quintile 
than white groups (OR 1.34, 95%CI 1.20-1.51), while no differences in deprivation between white and 
south Asian groups were evident.
After additionally accounting for age at diagnosis, mean HbA1c was lower in south Asian groups 
(β = -1.53, 95%CI -2.29, -0.77) and higher in black groups relative to white groups, (β = 1.88 95%CI 
0.76- 3.00). BMI, total cholesterol, and eGFR were more favourable in non-white groups compared to 
white groups at diagnosis (p<0.001), while fasting blood glucose, blood pressure and creatinine levels 
were better for south Asian groups only (p<0.034). The odds of having co-morbid macrovascular 
disease at diagnosis were reduced in south Asian groups and halved in black groups relative to white 
(South Asian OR 0.88, 95%CI 0.80-0.96, Black OR 0.50, 9%CI 0.43-0.58); no ethnic differences in the 
odds of having diagnosed microvascular disease were evident. Furthermore, non-white groups had 
markedly fewer prescriptions of antihypertensive and lipid lowering drugs in the 12 months preceding 
diagnosis, and reduced odds of having a CVD risk score over 10% relative to white groups (p<0.007) 
(Figure 2). 
3.2 Clinical management prior to diagnosis
In the 12 months prior to diagnosis, consultation frequency was higher for white groups (median 10, 
IQR 6-17) than for south Asian (median 9, IQR 5-15) and black groups (median 8, IQR 5-14). After 
adjustment for age at diagnosis, sex, deprivation, and clustering by practice, the consultation rate was 
significantly lower for black groups relative to white ( β = -0.60, 95%I -1.05, -0.21). Risk factor 
recording for south Asian groups was better than or equivalent to non-white groups for 9/10 risk 
factors of interest, and for black groups, risk factor recording was better or equivalent for 8/10 risk 
factors (Table 2).
93.3 Initiation of therapeutic and non-therapeutic management following diagnosis
After adjustment for age, sex, deprivation, baseline HbA1c, and clustering by practice, time to 
initiation of antidiabetic therapy was faster south Asian groups  (HR  1.10, 95%CI 1.07-1.14) and black 
groups relative to white (HR 1.18, 95%CI 1.12-1.23). Time to first NHS health check (South Asian HR 
1.30, 95%CI 1.10-1.54, Black HR 1.33, 95%CI 1.6-1.68) and offer of structured diabetes education 
(South Asian HR 1.17, 95%CI 1.10-1.24, Black HR 1.44, 95%CI 1.31-1.56) was also faster in south Asian 
and black groups relative to white. In contrast, time to first consultation, risk factor measurement and 
diabetes review was longer or equivalent for both non-white groups relative to white.  (Table 3). 
3.4 Sensitivity analysis
Compared to those of known ethnicity (n=126,331), individuals of unknown ethnicity (n=53,575) were 
younger at diagnosis (β = -1.13, 95%CI -1.32, -0.94) , had reduced odds of risk factors recording in the 
12 months prior to diagnosis for 9/10 measures, and slower initiation of therapeutic and non-
therapeutic management post diagnosis compared to those of known ethnicity (p<0.001). While 
individuals of unknown ethnicity had poorer control of HbA1c, FBG, and blood pressure, they had 
more favourable cholesterol, BMI and serum creatinine levels (p<0.009). Contrary to expectations, 
individuals of unknown ethnicity had greater odds of being in the most affluent quintile of deprivation 
relative to those of known ethnicity (OR 1.14, 95%CI 1.07, 1.21), and a lower prevalence of gestational 
diabetes, vascular disease, and medication use (p<0.001, appendix figures S2 S3 , appendix tables 
S1,S2).
4.0 Discussion
We report the findings of a large population-based cohort study examining ethnic differences in both 
the clinical characteristics and clinical management of type two diabetes at time of diagnosis. The 
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results show that, despite a lower consultation rate and higher burden of pre-diabetic states, south 
Asian and black groups had better capture of risk factors, a lower age at diagnosis, and better or 
equivalent cardio-metabolic profile at diagnosis. Initiation of antidiabetic treatment was faster for 
black and south Asian individuals, as was time to first NHS health check and time to offer of structured 
education. However, time to first consultation and measurement of risk factors was largely slower for 
non-white groups. 
Overall, our findings suggest that downstream inequalities in diabetes outcomes do not appear to 
stem wholly from inequalities around the time of initial diagnosis, and in fact, highlight several 
positive aspects of primary care-based diabetes management. Firstly, the similarity of microvascular 
disease between ethnic groups at time of diagnosis suggests that non-white groups are not being 
diagnosed at a more severe stage of diabetes progression, and that the latency between true onset of 
diabetes and clinical diagnosis does not disadvantage ethnic minority groups. Combined with the 
findings of pro-active treatment initiation and timely risk assessments, our findings suggest that the 
elevated burden of cardio-metabolic risk in non-white groups is being appropriately recognized by 
health care professionals. Delays in risk factor measurement and diabetes review may reflect lower 
burden of cardio-metabolic risk at time of diagnosis or may be indicative of growing ethnic disparities 
with respect to longer-term diabetes management.
4.1 Comparisons with existing literature
To date, only two other UK based studies have reported ethnic differences in clinical severity at initial 
diagnosis of type 2 diabetes.(21,22) The first, a London based study of 1,506 individuals, found that  
diagnosis was ten years earlier for both black and south Asian populations, and that both non-white 
groups had lower levels of glycaemia and vascular complications.(21) The second was a 2003 survey 
of 1,899 individuals with type 2 diabetes which reported equivalent access to diabetes care between 
black and white individuals- providing further support to our findings of equity between ethnic groups 
with respect to clinical care before and after diagnosis.(22)
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Improvements in both quality of diabetes care and risk factor profiles of people with type 2 diabetes 
in the UK may be related to several overlapping causes. Firstly, the introduction of the Quality and 
Outcomes Framework (QOF), which incentivises achievement of quality targets for the care of 
individuals with chronic conditions, has both improved overall standards of diabetes care and reduced 
variations in diabetes care provision. (23–25) However, one study found that, though QOF 
incentivisation had accelerated short-term improvements in blood pressure and cholesterol, ethnic 
disparities in HbA1c remained – a finding echoed in our own study which showed that black people 
had significantly higher HbA1c at diagnosis, despite equivalence of other risk factors.(26)
Secondly, awareness amongst health care practitioners about ethnic differences in cardio-metabolic 
risk has increased steadily and may be responsible for the pro-active management of diabetes in non-
white groups. Ethnicity has now been incorporated into clinical guidance documents for hypertension, 
obesity, type 2 diabetes, and smoking cessation.(27–29) Specifically, guidelines for the prevention of 
type 2 diabetes in people at high risk, specify that individuals from ethnic minority populations should 
be encouraged to undergo a risk assessment for type 2 diabetes.(20)  In May 2018, a new guideline 
for promoting health amongst ethnic minority groups, was published – indicating that further 
reductions in ethnic disparities may become apparent over time.(30) 
Thirdly, improvements in risk factor profiles at diagnosis may be part of a larger trend of decreasing 
vascular disease across the developed world.(31) A 2017 study of trends in type 2 diabetes incidence, 
prevalence and mortality in the UK found a 32% decrease in all-cause mortality between 2004-2014, 
and a 2% increase in prevalence, thought to be driven by better survival rather than increasing 
incidence.(32) The findings of our study reflect these emerging trends, with reductions in ethnic 
inequalities likely driven by temporal improvements in population levels of risk factors, quality of 
clinical care, awareness of established ethnic differences in outcomes, and increased effectiveness of 
novel pharmacological therapies. 
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4.3 Strengths 
The strengths and limitations of routine electronic health records (EHRs) for diabetes research have 
been comprehensively outlined in a recent review.(33) In this study, the sample size was large and 
drawn from a representative denominator population, allowing sufficient power to detect differences 
between the main ethnic groups in the UK. The cohort was identified using a validated algorithm, 
designed to minimize misclassification of diabetes type.(34)  In order to account for the step change 
in diabetes management following the introduction of QOF, entry into the study cohort was restricted 
to individuals diagnosed with type 2 diabetes from 2004 onwards. Recent improvements in the 
completeness of ethnicity recording in the CPRD as part of QOF have facilitated a more robust 
examination of ethnic differences in conditions managed largely in primary care. (17) Linkage to 
deprivation data enabled us to separate the influences of ethnicity and deprivation, which are often 
conflated when examining health disparities. Restricting the study sample to people with at least 6 
months of continuous registration prior to their initial diagnosis of type 2 diabetes ensured that 
diagnoses were truly incident and that all outcomes of interest were measured as close to initiation of 
diabetes management as possible. General practice characteristics such as size, and participation in 
local enhanced service schemes have been found to play a large role in observed variations in quality 
of diabetes care.(35) By accounting for the clustering of people within practices, we were able to 
appropriately account for the influence of practice level factors on ethnic disparities. 
4.2 Limitations
As EHRs are primarily used for patient care rather than research, data quality and completeness can 
vary significantly depending on the time-period, disease area, and indicator of interest. Though 
financial incentivisation has standardized many aspects of diabetes care, shared decision is now the 
preferred model for management of many long-term conditions.   As such, observed differences in 
diabetes indicators may be due to active choices by the individual and provider to deviate from 
standard management plans in order to manage competing priorities. Ethnicity data was not available 
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for 30% of the study cohort, which may have introduced bias. Since ethnicity data are unlikely to be 
missing at random, it would have been inappropriate to impute these data. Sensitivity analyses 
showed that individuals with unknown ethnicity were younger at diagnosis and, surprisingly, less 
deprived than those of known ethnicity. Coupled with the findings of heterogeneity in clinical profile 
at diagnosis (poorer risk factor levels but fewer co-morbidities), it is likely that this is a mixed group 
encompassing younger, healthier, and more affluent individuals  who may not need to access 
healthcare, and individuals who are less healthy, or less able to access care. Deprivation scores 
derived from the postcode of the general practice were used for 40% of participants without 
permissions for linkage to individual level data. The relationship between practice level and individual 
level deprivation will vary greatly between individuals, potentially underestimating the true 
confounding effect of deprivation on the association between ethnicity and diabetes when using 
practice level as a proxy.
The dataset did not include information on genetic risk factors, early life exposures, migration history, 
diet and exercise, or any measures of health seeking behaviour or differences in attitudes towards 
medications and thus unmeasured confounding may have influenced the results. Future studies 
combining routine EHRs with cohort studies such as the UK Biobank will be valuable in obtaining a 
complete picture of an individual’s health across the life course.
4.4 Conclusions
Overall, we find limited evidence of systematic ethnic inequalities in identification of type 2 diabetes 
and management of cardio-metabolic risk around the time of initial diagnosis.  Findings from this 
study may be illustrative of a wider trend of shrinking inequalities in diabetes care. Additional 
investigations into the origin and implications of missingness of ethnicity data are warranted. Future 
work examining the extent to which ethnic differences are explained by genetic factors and whether 
ethnic disparities manifest later in the care pathway, for example, in relation to long-term risk factor 
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control as suggested here, will be necessary to understand how patterns of ethnic disparities in risk 
factor control and long-term outcomes are evolving in the UK. 
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 *All models adjust for age at diagnosis, sex, deprivation, and clustering by practice 
Figure 2. Ethnic differences in clinical severity at type 2 diabetes diagnosis 
 
 
 
Table 1. Ethnic differences in clinical characteristics at time of initial Type 2 diabetes diagnosis 
    % complete White South Asian Black Other Mixed Unknown 
N     113,988 6,970 2,944 1,854 555 53,575 
Demographic characteristics Age at diagnosis (mean, SD) 100.0 63.2 (13.4) 52.6 (13.1) 55.1 (13.1) 56.3 (13.2) 54.6 (13.6) 62 (13.4) 
  Male, % 100.0 62810 (55.1) 3767 (54) 1498 (50.9) 1022 (55.1) 304 (54.8) 30643 (57.2) 
  Social Deprivation, % 100.0             
  Quintile 1 (Least deprived)   20889 (18.3) 880 (12.6) 169 (5.7) 302 (16.3) 86 (15.5) 11443 (21.4) 
  Quintile 2   22486 (19.7) 1081 (15.5) 264 (9) 262 (14.1) 87 (15.7) 8335 (15.6) 
  Quintile 3   25343 (22.2) 1456 (20.9) 611 (20.8) 368 (19.8) 120 (21.6) 9973 (18.6) 
  Quintile 4   22278 (19.5) 1605 (23) 820 (27.9) 477 (25.7) 117 (21.1) 13255 (24.7) 
  Quintile 5 (Most deprived)   22992 (20.2) 1948 (27.9) 1080 (36.7) 445 (24) 145 (26.1) 10569 (19.7) 
Health behaviours Smoking status, % 72.1             
  Non-Smokers   32098 (38.3) 3106 (70.6) 1227 (65.2) 683 (54.6) 189 (49.6) 16406 (43.2) 
  Current Smokers   18479 (22) 701 (15.9) 288 (15.3) 258 (20.6) 100 (26.2) 8037 (21.2) 
  Ex-Smokers   33282 (39.7) 593 (13.5) 367 (19.5) 311 (24.8) 92 (24.1) 13536 (35.6) 
Risk factor level (mean, SD) HbA1c, mmol/L 52.9 63.2 (22.9) 63.9 (22.7) 66.3 (25) 65 (23.5) 66.6 (24.3) 65.2 (23) 
  HbA1c, % 52.9 7.9 (2.1) 8 (2.1) 8.2 (2.3) 8.1 (2.2) 8.2 (2.2) 8.1 (2.1) 
  Fasting blood glucose 66.4 10.5 (5) 10.1 (4.7) 10.7 (5.6) 9.9 (4.5) 10.6 (5.3) 10.7 (5.1) 
  SBP, mmHg 88.1 142.9 (19.7) 135.5 (18.7) 140.3 (19.5) 138.2 (19.6) 139.2 (20.5) 143.4 (20.2) 
  DBP, mmHg 88.1 82.3 (11.6) 82.3 (11.3) 83.8 (11.4) 82.5 (11) 84 (11.7) 82.9 (11.8) 
  BMI, Kg/m2 63.6 32.3 (6.1) 29.7 (5.3) 31.8 (5.9) 30.1 (5.9) 31.3 (6.4) 32.3 (6.1) 
  Total cholesterol, mmol/L 78.2 5.2 (1.2) 5.3 (1.2) 5.3 (1.1) 5.3 (1.2) 5.4 (1.2) 5.3 (1.2) 
  Serum creatinine, mmol/L 87.0 86.7 (28.6) 78.6 (27.7) 88.5 (42.3) 79.2 (27) 82.4 (25.4) 85.1 (25.9) 
  ACR, mg/mmol 2.5 19.6 (46.7) 20.5 (44.3) 15.7 (25.3) 38.1 (70.7) 12.9 (10.8) 20.2 (51.7) 
CVD risk score (%) >10% risk in 10 years 17.6 79.1  58.4  50.8  64  53.6  78.3  
Pre-diabetic indicators+ Pre-diabetes   19007 (16.7) 1310 (18.8) 496 (16.8) 319 (17.2) 96 (17.3) 8693 (16.2) 
  Family history of diabetes   14471 (12.7) 1916 (27.5) 659 (22.4) 350 (18.9) 127 (22.9) 5941 (11.1) 
  Gestational diabetes*   784 (1.5) 237 (7.4) 72 (5) 41 (4.9) 15 (6) 293 (1.3) 
  Family history of CVD   50813 (44.6) 2874 (41.2) 858 (29.1) 660 (35.6) 212 (38.2) 23305 (43.5) 
Diagnosed co-morbidities (%)+ Any macrovascular disease   22122 (19.4) 720 (10.3) 211 (7.2) 184 (9.9) 49 (8.8) 8975 (16.8) 
  Any microvascular disease   4781 (4.2) 217 (3.1) 101 (3.4) 49 (2.6) 14 (2.5) 1994 (3.7) 
  Hypertension   57625 (50.6) 2320 (33.3) 1375 (46.7) 748 (40.3) 222 (40) 26000 (48.5) 
  CHD   19260 (16.9) 649 (9.3) 138 (4.7) 162 (8.7) 44 (7.9) 7746 (14.5) 
  Stroke   507 (0.4) 12 (0.2) 8 (0.3) 9 (0.5) 0.0 204 (0.4) 
  Heart failure   5117 (4.5) 133 (1.9) 90 (3.1) 33 (1.8) 8 (1.4) 2253 (4.2) 
  CKD   708 (0.6) 24 (0.3) 16 (0.5) 6 (0.3) 3 (0.5) 267 (0.5) 
  Retinopathy   2111 (1.9) 106 (1.5) 56 (1.9) 26 (1.4) 9 (1.6) 979 (1.8) 
  Neuropathy   2215 (1.9) 101 (1.4) 38 (1.3) 20 (1.1) 2 (0.4) 845 (1.6) 
Medications prescribed (%)+ Antihypertensives   69988 (61.4) 2796 (40.1) 1441 (48.9) 838 (45.2) 258 (46.5) 31095 (58) 
  Lipid lowering    52721 (46.3) 2566 (36.8) 926 (31.5) 729 (39.3) 190 (34.2) 22834 (42.6) 
 
*Baseline covariate data taken at the date closest to Type 2 diabetes diagnosis in the 12 months preceding diagnosis, (gestational diabetes among women only). 
+Pre-diabetic indicators, Diagnosed co-morbidities and medications assumed to be present if recorded and absent if not recorded 
 
 
 
Table 2. Risk factor recording and consultations in the 12 months prior to type 2 diabetes diagnosis 
 
  % with risk factor recorded Adjusted difference 
   White   South Asian   Black  South Asian vs. White Black vs. White 
 N       113,988            6,970            2,944              
 Risk Factors  %    %   %  OR 95%CI p.val OR 95%CI p.val 
 HbA1c               51.8               62.3               60.9  1.37 (1.30,1.45) <0.001 1.17 (1.08,1.27) <0.001 
 Glucose               66.2               60.8               59.4  1.02 (0.97,1.08) 0.455 0.88 (0.81,0.95) 0.002 
 Blood Pressure               88.9               85.0               87.0  0.99 (0.92,1.06) 0.700 1.08 (0.97,1.19) 0.162 
 BMI               64.1               64.6               64.6  0.98 (0.93,1.03) 0.345 1.00 (0.92,1.08) 0.950 
 Total Cholesterol               78.9               80.8               78.6  1.12 (1.06,1.19) <0.001 1.01 (0.92,1.09) 0.892 
 Creatinine               87.7               85.3               84.9  1.14 (1.07,1.21) <0.001 1.07 (0.97,1.17) 0.163 
 Urine ACR                 2.4                 1.9                 2.1  1.18 (0.96,1.44) 0.117 1.18 (0.89,1.57) 0.242 
 Smoking Status               73.6               63.1               63.9  0.72 (0.69,0.76) <0.001 0.75 (0.70,0.81) <0.001 
 Risk assessments                    
 NHS Health Check                 4.1                 8.4               10.2  1.55 (1.40,1.73) <0.001 1.49 (1.29,1.72) <0.001 
 CVD risk score               18.7               22.3               24.9  1.05 (0.98,1.12) 0.159 1.22 (1.11,1.35) <0.001 
Consultations Median (IQR) β CI95% p.val β CI95% p.val 
Number of consultations 10 (6-17) 9 (5-15) 8 (5-14) -0.10 (-0.40,0.18) 0.452 -0.60 (-1.05,-0.21) 0.003 
*Logistic and linear regression models adjusted for age at baseline, sex, deprivation, and clustering by practice 
Table 3. Time to therapeutic and non-therapeutic clinical management following type 2 diabetes diagnosis 
  % receiving clinical management Median time to first clinical event 
(months) 
Adjusted HR 
  White South 
Asian 
Black White South 
Asian 
Black SA vs. White Black vs. White 
N 113,988 6,970 2,944    HR CI95% p.val HR CI95% p.val 
First post-diagnosis consultation 99.9 99.7 99.8 0.1 0.1 0.1 0.84 (0.81,0.86) <0.001 0.92 (0.89,0.96) <0.001 
        
      
Initiation of antidiabetic therapy 73.2 80.9 78 3.6 2.2 1.8 1.10 (1.07,1.14) <0.001 1.18 (1.12,1.23) <0.001 
              
Risk Factor Measurement             
HbA1c 94.8 92.4 89.7 2.7 3.2 3.2 0.93 (0.91,0.96) <0.001 0.88 (0.84,0.91) <0.001 
Blood Glucose 61.7 58.1 56.2 10.5 10.3 9.2 0.94 (0.91,0.98) 0.001 0.96 (0.91,1.01) 0.125 
Urine ACR 59 53.4 56.4 11.4 12.2 10.6 1.01 (0.98,1.05) 0.504 1.05 (1.00,1.11) 0.055 
BMI 92.7 91.2 88.6 1.7 2.1 2.4 0.96 (0.94,0.99) 0.010 0.97 (0.93,1.01) 0.115 
Blood Pressure 96.3 94.2 93.5 1.4 1.6 1.4 0.91 (0.88,0.93) <0.001 1.00 (0.96,1.04) 0.872 
Total Cholesterol 92.5 90.2 87.6 3.7 4.3 4.1 0.99 (0.97,1.02) 0.667 0.97 (0.93,1.02) 0.220 
Smoking Status 93.2 90.4 86.6 3.0 3.4 3.6 0.90 (0.87,0.92) <0.001 0.87 (0.83,0.91) <0.001 
Serum Creatinine 94.3 90.7 88.3 3.2 4.0 3.8 0.94 (0.92,0.97) <0.001 0.93 (0.89,0.97) <0.001 
              
Diabetes Review             
Diabetes Review 82.4 81.1 75.9 6.0 6.7 6.8 1.03 (1.00,1.06) 0.076 1.03 (0.98,1.08) 0.194 
Retinopathy Screen 41.1 37.9 41.8 22.8 22.1 19.2 0.98 (0.94,1.02) 0.305 0.93 (0.87,0.98) 0.014 
Foot Examination 40 26.9 25.7 26.5 29.8 25.8 0.86 (0.81,0.90) <0.001 0.92 (0.85,0.99) 0.027 
Offer of dietary advice 6.3 3.3 1.5 47.6 43.2 38.2 0.81 (0.71,0.94) 0.005 0.64 (0.48,0.87) 0.004 
              
Structured diabetes education offered 17.2 22.5 25 48.3 40.2 31.0 1.17 (1.10,1.24) <0.001 1.44 (1.32,1.56) <0.001 
              
Risk Assessment             
CVD risk score 15.4 20.6 18.6 43.4 34.2 30.8 1.02 (0.96,1.09) 0.463 1.06 (0.96,1.16) 0.249 
NHS Health Check 1.7 2.8 3.1 52.1 44.9 38.1 1.30 (1.10,1.54) 0.002 1.32 (1.05,1.67) 0.019 
*All models adjust for age at baseline, sex, deprivation, raised HbA1c at baseline, and clustering by practice. Time to initiation of antidiabetic therapy restricted to those free from 
antidiabetic medication in 12 months prior to diagnosis date.   
Figure Legends 
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